Treatment options in nodular lymphocyte-predominant Hodgkin lymphoma

Dennis A Eichenauer; Andreas Engert

首页> 外文期刊>International journal of hematologic oncology. >Treatment options in nodular lymphocyte-predominant Hodgkin lymphoma

【24h】

Treatment options in nodular lymphocyte-predominant Hodgkin lymphoma

机译：结节性淋巴细胞为主的霍奇金淋巴瘤的治疗选择

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

SUMMARY?Nodular lymphocyte-predominant Hodgkin lymphoma accounts for approximately 5% of all Hodgkin lymphoma cases. Although this entity is characterized by immunohistological and clinical features such as a consistent expression of CD20 on the malignant lymphocyte-predominant cells and a more indolent clinical course resembling indolent non-Hodgkin lymphoma, treatment is often similar to classical Hodgkin lymphoma. Other approaches appear possible but data are scarce. Especially the ultimate role of anti-CD20 antibodies, the optimal first-line chemotherapy protocol and the value of high-dose chemotherapy followed by autologous stem cell transplantation in relapsed disease are undefined to date. The present article aims at summarizing and discussing the most recent publications on treatment options in nodular lymphocyte-predominant Hodgkin lymphoma.

机译：小结结节性淋巴细胞为主的霍奇金淋巴瘤约占所有霍奇金淋巴瘤病例的5％。尽管该实体的特征是免疫组织学和临床特征，例如在恶性淋巴细胞为主的细胞上CD20的一致表达，以及类似于惰性非霍奇金淋巴瘤的更惰性的临床病程，但治疗通常与经典霍奇金淋巴瘤相似。其他方法似乎可行，但数据很少。迄今为止，尤其是抗CD20抗体的最终作用，最佳的一线化疗方案以及大剂量化疗后再进行自体干细胞移植在复发性疾病中的价值尚不确定。本文旨在总结和讨论有关结节性淋巴细胞为主的霍奇金淋巴瘤的治疗选择的最新出版物。

著录项

来源
《International journal of hematologic oncology.》 |2013年第4期|共6页
作者
Dennis A Eichenauer; Andreas Engert;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Validation of CD137 Immunohistochemical Stain on Paraffin-Embedded Tissue as a Marker to Facilitate Distinction Between Classic Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, and Anaplastic Large Cell Lymphoma [J] . Carbone Peter N., Zhang Qian-Yun Archives of pathology & laboratory medicine . 2019,第3期

机译：将CD137免疫组织化学染色在石蜡嵌入式组织中的验证作为标记，以促进经典霍奇金淋巴瘤，结节淋巴细胞 - 主要霍格金淋巴瘤，T细胞/组织细胞富含大B细胞淋巴瘤和血压大细胞淋巴瘤
2. Lymphocyte-Rich Classical Hodgkin Lymphoma: A Case with Difficulty in Distinguishing from Nodular Lymphocyte-Predominant Hodgkin Lymphoma [J] . Jun Sakai, Ken Tanae, Naoki Takahashi, Journal of clinical and experimental hematopathology : . 2015,第1期

机译：富含淋巴细胞的经典霍奇金淋巴瘤：难以区分结节性淋巴细胞为主的霍奇金淋巴瘤的一例
3. Characteristics and Outcomes of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Versus Those With Classical Hodgkin Lymphoma: A Population-Based Analysis [J] . Gerber Naamit K., Atoria Coral L., Elkin Elena B., International Journal of Radiation Oncology, Biology, Physics . 2015,第1期

机译：结节性淋巴细胞为主的霍奇金淋巴瘤患者与典型霍奇金淋巴瘤患者的特征和结果：基于人群的分析
4. Development of Single Domain Antibodies for Diagnosis and Treatment of Naturally Occurring Canine Lymphoma: An Animal Model for Human Non-Hodgkin Lymphoma [C] . Joana Dias, Solange Gil, Belmira Carrapico, PEGS . 2015

机译：天然犬淋巴瘤诊断和治疗单结构域抗体的发展：人非霍奇金淋巴瘤的动物模型
5. Targeting the translational machinery as a novel treatment strategy for non-Hodgkin lymphoma. [D] . Hagner, Patrick R. 2010

机译：针对非霍奇金淋巴瘤的新型治疗策略，以翻译机制为目标。
6. Utility of LRF/Pokemon and NOTCH1 Protein Expression in the Distinction of Nodular Lymphocyte-Predominant Hodgkin Lymphoma and Classical Hodgkin Lymphoma [O] . Olga Bohn, Takahiro Maeda, Alexander Filatov, -1

机译：LRF /口袋妖怪和NOTCH1蛋白表达在结节性淋巴细胞为主的霍奇金淋巴瘤和经典霍奇金淋巴瘤的区分中的效用
7. Characteristics and Outcomes of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Versus Those With Classical Hodgkin Lymphoma: A Population-Based Analysis [O] . Gerber Naamit K., Atoria Coral L., Elkin Elena B., 2015

机译：结节性淋巴细胞为主的霍奇金淋巴瘤患者与典型霍奇金淋巴瘤患者的特征和结果：基于人群的分析

Treatment options in nodular lymphocyte-predominant Hodgkin lymphoma

摘要

著录项

相似文献

相关主题

期刊订阅